An Open-label Phase II Study of Lorvotuzumab Mertansine (IMGN901) in CD56 Expressing Hematological Malignancies
Phase of Trial: Phase II
Latest Information Update: 19 Jun 2017
At a glance
- Drugs Lorvotuzumab mertansine (Primary)
- Indications Leukaemia
- Focus Therapeutic Use
- 13 Jun 2017 Status changed from active, no longer recruiting to completed.
- 03 Aug 2016 Status changed from recruiting to active, no longer recruiting.
- 07 Mar 2016 Planned primary completion date changed from 1 May 2017 to 1 May 2018, according to ClinicalTrials.gov record.